RxDoctor Payments Data

Amy Trace, MD

Internal Medicine · Warrenton, VANPI 1841308566

Payments from drug & device makers

$3,333in general payments, 2019–2025

Across 204 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$679
  • AbbVie$304
  • Pfizer$273
  • Esperion Therapeutics, Inc.$238
  • Amgen$216
  • Lilly USA, LLC$196
  • plus $1K from 30 others

What the payments were for

  • Food & beverage$3,333100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,333 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$103,536
Medicare patients
202
Services billed
2,668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$120,486
RybelsusSemaglutide26$55,448
MounjaroTirzepatide44$45,474
EliquisApixaban19$18,503
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$15,839
MyrbetriqMirabegron21$13,100
LinzessLinaclotide15$8,129
SymbicortBudesonide/Formoterol Fumarate20$5,412
Dexlansoprazole DrDexlansoprazole14$4,017
Levothyroxine Sodium303$3,203
SynthroidLevothyroxine Sodium51$2,462
Rosuvastatin Calcium252$2,328
Atorvastatin Calcium181$1,789
Colchicine11$1,748
Methylphenidate ErMethylphenidate Hcl13$1,560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$679$175,933120 claims
Lilly USA, LLCMounjaro$196$45,47444 claims
PfizerEliquis$273$18,50319 claims
GSKTrelegy Ellipta$76$15,83918 claims
Astellas Pharma US IncMyrbetriq$82$13,10021 claims
AbbVieLinzess, Synthroid$304$10,59166 claims
AstraZenecaSymbicort$63$5,41220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Warrenton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →